英夫利西单抗加速诱导方案治疗激素难治性急性重症结肠炎:多中心回顾性队列研究
该多中心回顾性队列研究纳入131例接受英夫利西单抗挽救治疗的激素难治性急性重症溃疡性结肠炎住院患者,其中102例标准诱导、29例加速诱导。结论认为加速诱导方案可能与短期而非长期结肠切除率降低相关。
核心结论
- 在倾向性评分匹配队列中,激素难治性急性重症溃疡性结肠炎患者接受加速诱导方案的短期结肠切除率似乎低于标准诱导方案,但长期结肠切除率无差异。
研究设计与样本
- 多中心回顾性队列研究,纳入131例住院接受英夫利西单抗挽救治疗的激素难治性急性重症溃疡性结肠炎患者,其中102例标准诱导、29例加速诱导;采用倾向性评分最优卡钳匹配分析。
临床怎么用
- 对于激素难治性急性重症溃疡性结肠炎住院患者,加速英夫利西单抗诱导方案可能与短期结肠切除率降低相关,但长期获益未显现。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accelerated induction regimens of infliximab have been proposed to improve response rates in patients with steroid-refractory acute severe colitis. AIM: To determine the differences in outcome for acute severe ulcerative colitis between accelerated and standard-dose infliximab METHODS: We collected data on hospitalised patients receiving differing regimens of rescue therapy for steroid-refractory acute severe ulcerative colitis. Our primary outcome was 30-day colectomy rate. Secondary outcomes were colectomy within index admission, and at 90 days and 12 months. We used propensity score analysis with optimal calliper matching using high risk covariates defined a priori to reduce potential provider selection bias. RESULTS: We included 131 patients receiving infliximab rescue therapy; 102 received standard induction and 29 received accelerated induction. In the unmatched cohort, there was no difference by type of induction in the 30-day colectomy rates (18% vs 20%, P = .45), colectomy during index admission (13% vs 20%, P = .26) or overall colectomy (20% vs 24%, P = .38). In the propensity score-matched cohort of 52 patients, 30-day colectomy (57% vs 27%, P = .048) and index admission colectomy (53% vs 23%, P = .045) rates were higher in those receiving standard induction compared to accelerated induction but there was no difference in overall colectomy rates (57% vs 31%, P = .09). There was no significant difference in length of stay or in complication and infection rates. CONCLUSION: In a propensity score-matched cohort, steroid-refractory acute severe ulcerative colitis patients, short-term, but not long-term, colectomy rates appear to be lower in those receiving an accelerated induction regimen.
引用
- Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019. PMID: 31456297. doi:10.1111/apt.15456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。